Abivax (ABVX) Non-Current Debt (2021 - 2026)
Abivax (ABVX) posted quarterly Non-Current Debt of $1.3 million for Q1 2026, down 94.97% year-over-year from $25.6 million in Q1 2025, and down 14.95% quarter-over-quarter from $1.5 million in Q4 2025.
Abivax (ABVX) Non-Current Debt (2021 - 2026) Analysis & Trends
Abivax's Non-Current Debt history runs 6 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Non-Current Debt fell 94.97% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 94.97% YoY), while the FY2025 annual figure was $1.5 million, down 97.95% from the prior year.
- Non-Current Debt for Q1 2026 stood at $1.3 million, down from $1.5 million in the prior quarter.
- The five-year high for Non-Current Debt was $73.8 million in Q4 2024, with the low at $1.3 million in Q1 2026.
- The 5-year median for Non-Current Debt is $27.9 million (2025), against an average of $28.9 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Debt jumped 157.77% in 2023, then sank 97.95% in 2025.
- Abivax's Non-Current Debt stood at $16.6 million in 2022, then surged by 157.77% to $42.7 million in 2023, then jumped by 72.8% to $73.8 million in 2024, then tumbled by 97.95% to $1.5 million in 2025, then slipped by 14.95% to $1.3 million in 2026.
- Business Quant data shows ABVX's Non-Current Debt at $1.3 million in Q1 2026, $1.5 million in Q4 2025, and $29.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Abivax | 9.39 Bn | 9.39 Bn | - | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 1.52 Mn |
| Sep 30, 2025 | 29.50 Mn |
| Jun 30, 2025 | 27.89 Mn |
| Mar 31, 2025 | 25.64 Mn |
| Dec 31, 2024 | 73.81 Mn |
| Jun 30, 2024 | 41.60 Mn |
| Dec 31, 2023 | 42.71 Mn |
| Dec 31, 2022 | 16.57 Mn |
| Dec 31, 2021 | 57.47 Mn |